News

Spironolactone's Heart Failure Benefit Outweighs Hyperkalemia Risk

Publish date: September 28, 2012

 

AT THE ANNUAL MEETING OF THE HEART FAILURE SOCIETY OF AMERICA

Dr. Vardeny reported having no relevant conflicts of interest. The RALES trial was sponsored by Searle, manufacturer of Aldactone.

Pages

Recommended Reading

2-D Echo Is Inadequate Cardiomyopathy Screen in Childhood Cancer Survivors
MDedge Family Medicine
Fitness Curbs Mortality in Men With Diabetes
MDedge Family Medicine
Exercise Cuts Depressive Symptoms in Heart Failure Patients
MDedge Family Medicine
LCZ696 Promising in Subset of Heart Failure Patients
MDedge Family Medicine
Third Universal MI Definition Unveiled
MDedge Family Medicine
Evidence Mounts on Heart Failure After Trastuzumab in Breast Cancer Survivors
MDedge Family Medicine
Nurse-Led Case Management Cuts HF Readmissions, Mortality
MDedge Family Medicine
FDA Panel Votes Against Approval of Hyponatremia Drug
MDedge Family Medicine
FDA Reviewing Possible Heart Failure Risk with Pramipexole
MDedge Family Medicine
Heart Failure Hospitalization, Deaths Decline with Depression Intervention
MDedge Family Medicine